Related Experiment Video
Updated: Aug 7, 2026
Comparative in vivo Study of gp96 Adjuvanticity in the Frog Xenopus laevis
Published on: September 16, 2010
The dual nature of specific immunological activity of tumor-derived gp96 preparations
R Y Chandawarkar1, M S Wagh, P K Srivastava
1Center for Immunotherapy of Cancer and Infectious Diseases (MC1601), University of Connecticut School of Medicine, Farmington, Connecticut 06030-1601, USA.
Abstract:
Mice immunized with optimal doses of autologous tumor-derived gp96 resist a challenge with the tumor that was the source of gp96. Immunization with quantities of gp96 5-10 times larger than the optimal dose does not elicit tumor immunity. This lack of effect is shown to be an active, antigen-specific effect, in that immunization with high doses of tumor-derived gp96, but not normal tissue-derived gp96, downregulates the antitumor immune response. Furthermore, immunization with fractionated doses of gp96 elicits the same kind and level of response as elicited by a single dose equivalent to the total of the fractionated doses. This is true of the tumor-protective doses as well as the high downregulatory doses of gp96. The downregulatory activity can be adoptively transferred by CD4(+) but not CD8(+) T lymphocytes from mice immunized with high doses of gp96. These observations indicate that immunization with gp96 induces a highly regulated immune response that, depending upon the conditions of immunization, results in tumor immunity or downregulation.
Insights
Mice immunized with optimal doses of tumor-derived heat shock protein gp96 develop tumor immunity. High doses of gp96 actively suppress antitumor responses, mediated by CD4+ T cells, indicating a regulated immune response.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Heat shock proteins, such as gp96, play complex roles in immune regulation.
- Tumor-derived gp96 has been investigated as a potential cancer vaccine.
- The dose-dependent effects of gp96 on antitumor immunity are not fully understood.
Purpose of the Study:
- To investigate the dose-dependent immunomodulatory effects of autologous tumor-derived gp96.
- To determine the mechanisms underlying gp96-induced tumor immunity and immune suppression.
- To explore the potential of gp96 as a therapeutic agent in cancer treatment.
Main Methods:
- Mice were immunized with varying doses of autologous tumor-derived gp96.
- Tumor challenge experiments were performed to assess tumor immunity.
- Antigen-specific immune responses were analyzed.
- Adoptive transfer experiments using T lymphocytes were conducted.
Main Results:
- Optimal doses of tumor-derived gp96 induced resistance to tumor challenge.
- High doses (5-10 times optimal) of gp96 suppressed antitumor immunity in an antigen-specific manner.
- This suppressive effect was transferable via CD4+ T lymphocytes.
- Fractionated doses of gp96 produced similar immune responses to single equivalent doses.
Conclusions:
- Immunization with gp96 can elicit either tumor immunity or immune downregulation, depending on the dose.
- High-dose gp96-induced suppression is an active, antigen-specific process mediated by CD4+ T cells.
- These findings highlight the critical role of dose in gp96-based immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...